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The zebrafish, with its combination of forward genetics and vertebrate biology, has great potential as a cancer model system.
Cancer is an unfortunate reality for millions of humans world-
wide, and a fact of life for all vertebrate organisms. Although
invertebrates such as nematodes and flies can develop abnor-
malities in cell proliferation, what we recognize clinically and
pathologically as cancer is present almost exclusively in verte-
brates, from fish to humans. Thus, to understand the formation,
growth, and spread of malignant tumors, vertebrate models are
necessary.
We propose that the zebrafish is an ideal vertebrate system
in which to model cancer. Despite the more than 300 million
years separating the last common ancestor of fish and humans,
the biology of cancer is very much the same in these two organ-
isms. Cancer is commonly seen in fish in the wild, and straight-
forward assays involving water-borne carcinogen exposure
have demonstrated that teleosts develop a wide variety of
benign and malignant tumors in virtually all organs, with a his-
tology closely resembling that of human tumors (Hawkins et al.,
1985; Spitsbergen et al., 2000; Figure 1). As in humans, cancer
in fish is a genetic disease, as shown by the melanomas that
develop in Xiphophorus hybrids (Walter and Kazianis, 2001).
A comparison of the human genome sequence and the
soon to be completed zebrafish sequence demonstrates con-
servation of cell-cycle genes, tumor suppressors, and onco-
genes. Beyond comparative genomics, there are many advan-
tages to modeling cancer in the zebrafish system (Patton and
Zon, 2001; Figure 2). For example, large scale, forward genetic
screens can be targeted to these highly conserved cancer path-
ways. Although cancer is primarily a disease of adults, mutage-
nesis screens could be designed to examine cell-cycle pheno-
types in the transparent, rapidly developing embryos. Examples
of such screens already underway include those focusing on
cell proliferation (J.L.S., J.F.A., and L.I.Z., unpublished data)
and cell differentiation and genomic instability (K. Cheng, per-
sonal communication). Genetic screens in yeast, Drosophila,
and C. elegans have already revealed key genes regulating the
cell cycle, cell proliferation, and apoptosis. Similar screens in
the zebrafish would examine the conservation of gene function
in these biological pathways, and establish any vertebrate-spe-
cific events that lead to cancer. Most importantly, via the car-
cinogenesis assay, the zebrafish system provides a direct way
to test if a mutation causing an embryonic phenotype also caus-
es a cancer predisposition in adults.
Once a cancer-related mutation is found, it is possible to
identify interacting genes via suppressor/enhancer screens. In
zebrafish, it is possible to perform mutagenesis-based modifier
screens and directly address the role of the modifier in cancer,
because a modifier of the embryonic phenotype may reduce the
cancer predisposition in adults. Imagine using a zebrafish strain
with a tumor suppressor gene mutation to find a second gene
which, when inactivated, prevents cancer formation. This modi-
fier becomes an excellent target for an antineoplastic drug.
In addition to traditional genetic screens, the zebrafish sys-
tem is amenable to chemical genetic screens. Large numbers of
embryos can be arrayed into multiwell plates containing water
and aliquots of small molecules from chemical libraries
(Peterson et al., 2000; H.M.S., R. Murphey, and L.I.Z., unpub-
lished data). Chemical screens using embryos would select for
drugs active in a multicellular organism, an advantage over tra-
Figure 1. Histology of cholangiocarcinoma in
human and zebrafish
Cholangiocarcinoma is a malignant bile duct
neoplasm that occurs in both humans and
zebrafish. The histologic appearance, including
atypical nuclei, haphazard arrangement of
irregularly shaped glands, and increased mitot-
ic activity, is very similar in the two organisms.
Bar is 50 µm.
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ditional screens using transformed cell lines or in vitro protein
binding assays. Embryos exhibit many features of cancer,
including rapidly dividing cells, extensive apoptosis, and vigor-
ous angiogenesis. Screens for compounds that affect these
embryonic properties could identify compounds that are useful
for the treatment of cancer or are tools to study cancer path-
ways. For instance, in this issue of Cancer Cell, Chan et al.
(2002) demonstrate that a specific inhibitor of the vascular-
endothelial growth factor, flk1, leads to defective angiogenesis.
Such an angiogenesis inhibitor could be formally tested as an
antineoplastic agent in a cancer-prone zebrafish mutant. A par-
ticularly exciting approach would be to combine the power of
zebrafish genetics with chemical genetics by performing a
chemical suppressor/enhancer screen on a zebrafish cancer
model. One of the major challenges in the field will be develop-
ment of high-throughput methods to screen compounds using
embryos.
The mouse is an extremely important cancer model, based
both on its similarity to humans and on the many tools that have
been developed (Tuveson and Jacks, 2002). In order for the
zebrafish to advance as a cancer model system, researchers
will have to develop comparable technologies. Establishing
growth of tumor cells both in cell culture and as xenografts or
allografts would be invaluable.Transgenic lines could be used to
express oncogenes, or to delineate gene expression through
the use of green fluorescent protein (GFP). Tissue-specific,
inducible, or recombinase-based transgenics are needed, simi-
lar to mouse models. While gene inactivation by homologous
recombination remains to be developed, rapid analysis of gene
function in zebrafish is possible using morpholinos (Nasevicius
and Ekker, 2001). Morpholinos are antisense, chemically modi-
fied oligonucleotides typically directed against the 5′ region of
the coding sequence of a gene and have been successfully
used to phenocopy many mutants. This gene “knock down”
approach is effective during embryogenesis, but the morpholi-
nos degrade after about 4 days.Thus, the morpholino technique
does not permit assessment of the long-term effects of gene
inactivation. Nevertheless, this 4 day time period is adequate to
evaluate cellular processes related to
cancer biology and determine if the path-
ways found in mammals are present in
the fish.
To facilitate the use of zebrafish as a
forward genetic tool, the speed and effi-
ciency of mutant screening and gene
cloning needs to be improved. For exam-
ple, while ethylnitrosourea (ENU) muta-
genesis is relatively efficient, recovery of
mutations is still time-consuming. The
Sanger Center sequence of the
zebrafish genome, taken together with
trans-NIH efforts in both genetics and
genomics, will greatly help. A different
approach is the use of retroviral insertions (Amsterdam et al.,
1999) or transposons, which facilitates cloning of the mutant
gene. The power of any screen to detect mutations depends
critically on the tools used to detect the phenotype. At this point,
relatively few commercial antibodies exist that recognize
zebrafish cell cycle, signaling, and apoptosis-related proteins.
One alternative may be the use of transgenic lines; GFP
reporters that mark specific aspects of cell proliferation and sur-
vival could be used both for genetic screens and high-through-
put small molecule screens.
The zebrafish cancer system can be viewed as a combina-
tion of vertebrate tumor biology, classical and chemical genet-
ics, and genomics. Beginning with the pioneering work of
Streisinger and colleagues, the zebrafish was envisioned as an
excellent model system for complex biology.The large-scale for-
ward genetic screens in Tübingen and Boston in the 1990s fur-
thered the system in order to understand early embryonic
development (Driever et al., 1996; Haffter et al., 1996). Many of
the mutants obtained in these screens represent animal models
of rare genetic diseases. Now, we propose that the zebrafish be
used to attack a common disease, cancer.The magnitude of the
challenges facing zebrafish cancer research is matched by the
great promise of the system to discover novel cancer genes, to
probe the interactions among these genes, and to identify
chemotherapeutic and chemopreventive agents in the context
of a living, vertebrate organism.
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